Fulcrum Therapeutics (FULC) EBT Margin (2020 - 2024)
Fulcrum Therapeutics (FULC) posted quarterly EBT Margin of 50.27% for Q2 2024, up 474277.0% year-over-year from N/an in Q3 2023, and up 101.02% quarter-over-quarter from 4949.03% in Q4 2023.
Powered by 
Analysis
Fulcrum Therapeutics (FULC) EBT Margin (2020 - 2024) Analysis & Trends
Fulcrum Therapeutics (FULC) has reported EBT Margin for 5 consecutive years, with 50.27% the latest figure, recorded in Q2 2024.
- In Q2 2024, EBT Margin rose 474277.0% year-over-year to 50.27%; the TTM figure through Jun 2025 stood at 163.85% (down 3107.0% YoY), while the FY2024 annual figure was 91.73%, up 969387.0% from the prior year.
- EBT Margin rose to 50.27% in Q2 2024 per FULC's latest filing, from 4949.03% in the prior quarter.
- Across five years, EBT Margin topped out at 50.27% in Q2 2024 and bottomed at 14191.19% in Q1 2023.
- Historically, EBT Margin has averaged 3453.14% across 5 years, with a median of 2663.44% in 2022.
- Annual changes were most pronounced in 2023 — EBT Margin plunged 1056477 bps — and 2024, when it soared 474277 bps.
- Fulcrum Therapeutics' EBT Margin stood at 421.8% in 2020, then plunged by 455 bps to 2342.8% in 2021, then plunged by 86 bps to 4358.86% in 2022, then decreased by 14 bps to 4949.03% in 2023, then soared by 101 bps to 50.27% in 2024.
- Business Quant data shows FULC's EBT Margin at 50.27% in Q2 2024, 4949.03% in Q4 2023, and 5304.35% in Q3 2023.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 41.75% |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 35.61% |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 35.78% |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -528.97% |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 18.33% |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 13.77% |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 12.09% |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -2.67% |
| 10 | Fulcrum Therapeutics | 293.24 Mn | 293.24 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2024 | 65.70% |
| Dec 31, 2023 | -2,842.25% |
| Sep 30, 2023 | -3,164.30% |
| Jun 30, 2023 | -3,163.75% |
| Mar 31, 2023 | -9,421.69% |
| Dec 31, 2022 | -3,815.33% |
| Sep 30, 2022 | -2,006.59% |
| Jun 30, 2022 | -1,817.91% |
| Mar 31, 2022 | -1,029.75% |
| Dec 31, 2021 | -476.20% |
| Sep 30, 2021 | -419.78% |
| Jun 30, 2021 | -449.37% |
| Mar 31, 2021 | -355.92% |
| Dec 31, 2020 | -419.41% |
| Sep 30, 2020 | -1,026.08% |
| Jun 30, 2020 | -789.50% |
| Mar 31, 2020 | -2,513.20% |